Fig. 1 Acute LY379268 and olanzapine treatment restore NMDA-R binding density levels in several brain regions of two-hit NRG1 HET (PCP) mice. Wild type mice (WT) and neuregulin 1 heterozygous transmembrane domain knockout mice (HET) received chronic phencyclidine (PCP) or saline (SAL) treatment for 14 days and an acute treatment of LY379268 or olanzapine after 14 days washout. N-methyl-D-aspartate receptors (NMDA-R) binding was quantified in the prefrontal cortex (PFC), caudate putamen (CPu), Nucleus accumbens (NAcb), whole hippocampus (Hipp) and subregions (CA1), dentate gyrus (DG), lateral septum (LS). Data presented as mean binding density nCi/mg tissue ± standard error of the mean (n = 6), Statistical significance:*P < 0.05, **P < 0.01, ***P < 0.001 as compared to WT(SAL) vehicle Fig. 2 Acute LY379268 and olanzapine treatment restore GABAA-R binding density levels in several brain regions of two-hit NRG1 HET (PCP) mice. Wild type mice (WT) and neuregulin 1 heterozygous transmembrane domain knockout mice (HET) received chronic phencyclidine (PCP) or saline (SAL) treatment for 14 days and an acute treatment of LY379268 or olanzapine after 14 days washout. Gammaaminobutyric acid receptor A (GABAA-R) binding was quantified in the prefrontal cortex (PFC), caudate putamen (CPu), Nucleus accumbens (NAcb), whole hippocampus (Hipp) and subregions (CA1), dentate gyrus (DG), lateral septum (LS). Data presented as mean binding density nCi/mg tissue ± standard error of the mean (n = 6), Statistical significance:*P < 0.05, **P < 0.01, ***P < 0.001 as compared to WT(SAL) vehicle Fig. 3 Acute LY379268 treatment restores positive correlation between NMDA-R and GABAA-R binding levels across brain regions in two-hit NRG1 HET(PCP) mice. Spearman's correlation plots depicting the relationship between NMDA-R and GABAA-R binding levels across all brain regions, following the different modelling strategies and acute treatment options. Abbreviations: wild type mice (WT), neuregulin 1 heterozygous transmembrane domain knockout mice (NRG1), chronic phencyclidine treatment (PCP), chronic saline treatment (SAL) *P > 0.05, **P > 0.01
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